微小RNA-107及B/T淋巴细胞弱化因子在胰腺癌中的潜在应用进展

Progress on potential application of microRNA-107 and B and T lymphocyte attenuator in pancreatic cancer

胰腺癌是消化道常见的恶性肿瘤之一,由于发病隐匿,早期多无症状,诊断困难。胰腺癌诊断主要借助影像学及血清标志物检查,手术治疗为其主要的治疗手段。但由于被发现时多为疾病晚期,错过手术最佳时机,因此预后极差,生存期较短。有研究表明微小RNA(miRNA,miR)在多种肿瘤的发生发展中起关键作用,其中miR-107表达于胰腺癌组织及血液中,与胰腺癌的发生侵袭有关,且有相关数据库表明miRNA能够靶向调控B/T淋巴细胞弱化因子(BTLA)。BTLA与其配体结合传递共抑制信号,在机体抗肿瘤免疫应答中发挥负性调节作用,并与肿瘤的免疫逃逸机制相关,可能成为肿瘤生物治疗潜在的靶点。本文将通过对miR-107与BTLA进行介绍,预测它们可能是胰腺癌的治疗靶点,有望成为胰腺癌诊断及预后标志物。

Pancreatic cancer is one of the common malignant tumors of digestive tract and is difficult to diagnose because it is characterized by insidious onset and asymptomatic early-stage.The diagnosis of pancreatic cancer mainly relies on imaging and serum tumor markers,and the main treatment method is surgery.However,due to being discovered in the advanced stage of the disease and missing the best opportunity for surgery,the prognosis is extremely poor and short-term survival.Studies have shown that microRNAs(miRNAs,miR)play a key role in the genesis and development of a variety of tumors,of which miR-107 is expressed in pancreatic cancer tissue and blood,which is related to the occurrence and invasion of pancreatic cancer.In some databases,it has been determined that miRNAs can target and regulate B and T lymphocyte attenuator(BTLA).BTLA with its ligand transmits coinhibitory signals and plays a negative regulatory role in the body s anti-tumor immune response,which is related to the immune escape mechanism of tumors and is likely to become a potential target of tumor biotherapy.This article will elaborate miR-107 and BTLA to predict that they may be therapeutic targets of pancreatic cancer and are expected to become diagnostic and prognostic markers of pancreatic cancer.